ClinicalTrials.gg
Active, not recruitingNCT06019676ADAPT-PUpdated Sep 18, 2025

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients

An observational study in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), sponsored by Royal Marsden NHS Foundation Trust. Active, not recruiting at 12 sites in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Royal Marsden NHS Foundation Trust · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
170
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust — 8 open to participants now, 10 under way, 1 of them phase 3. Prostatic Neoplasms · Royal Marsden NHS Foundation Trust.

Started
2023
with 1 other
Observational
7 of 21
4 open now
Registered
14th of 21
by date

Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 14th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, or all of them as a file.
02

Study summary

The ADAPT study is an observational study of apalutamide, which can be given to patients with hormone sensitive metastatic prostate cancer as standard of care. The clinical decision for patients to have apalutamide as part of their management plan will be decided by the clinician. The patient will only be approached about the ADAPT study if they decide they want to have apalutamide as part of their management.

The aims of the ADAPT study include documenting the biochemical effectiveness, as determined by the Prostate-Specific Antigen (PSA) and impact of apaluatmide on health related quality of life. The blood test for PSA is regularly monitored as standard of care.

Additionally, the impact of apalutamide on fatigue, cognitive function, patients reported outcomes, health related quality of life will be evaluated using patient questionnaires answered at defined timepoints. The questionnaires will be sent either electronically or via post at week 12, 24, 36, 48, 72 and 104 weeks after commencement of apalutamide.

Currently, the majority of data regarding tolerability and biochemical response to apalutamide has been from large phase III trials, where there are strict eligibility criteria. Real-world data as from the ADAPT study can provide valuable complementary data to randomised controlled trials, which can be used to address the 'generalizability' limitations of randomised control trials and can provide evidence on the external validity of their findings. This information can advance knowledge of patterns of care, treatment effectiveness and side-effects and inform clinical practice to improve outcomes.

03

Conditions studied

  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Males 18 years of age or older, with metastatic hormone sensitive prostate cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male 18 years of age or older
  • confirmed diagnosis of adenocarcinoma of the prostate with both:
  • hormone sensitive prostate cancer
  • Treatment decision for apalutamide by clinician

Exclusion criteria

Exclusion Criteria:

  • Non- prostate cancer
  • Prior chemotherapy / abiraterone / apalutamide / darolutamide / enzalutamide for prostate cancer
  • Unable to complete patient reported outcome questionnaires
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
170 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with mHSPC and treatment decision for apalutamide by clinician
06

What researchers measure

Primary outcomes

  1. Undetectable PSA rate (defined as PSA <0.2ng/ml by end of year 1 and year 2) in mHSPC patients receiving apalutamide

    Time frame: August 2023 - April 2027

Secondary outcomes

  1. The impact of apalutamide on fatigue, assessed using patient-reported Brief Fatigue Inventory questionnaire

    Time frame: August 2023 - April 2027

  2. The impact of apalutamide on cognitive function, using patient-reported FACT-Cog questionnaire

    Time frame: August 2023 - April 2027

  3. The impact of apalutamide on health-related quality of life, using patient-reported EQ-5D-5L questionnaire

    Time frame: August 2023 - April 2027

Other outcomes

  1. Health care professional experience on the use of apalutamide, assessed using Health Care Professional Questionnaire

    Time frame: August 2023 - April 2027

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Apr 2027, 42 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 42 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 31, 2023
StartActual
Sep 26, 2023
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06019676
Collaborators
Janssen, LP
Responsible party
Sponsor
First posted
Aug 31, 2023
Start date
Sep 26, 2023
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Sep 18, 2025

Study contacts

Julia Murray, Dr.
principal investigator · The Royal Marsden Hospital, NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion